Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035, Pharma Intelligence

Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035, Pharma Intelligence

  • July 2018 •
  • 318 pages •
  • Report ID: 5780017 •
  • Format: PDF
Disease Overview
Chronic kidney disease (CKD) is characterized by decreased kidney function and kidney damage. Damaged renal tissue has a diminished ability to produce erythropoietin, a hormone that stimulates red blood cell production. Consequently, patients with CKD often experience anemia, defined as a reduction in red blood cells or hemoglobin levels. The risk of anemia increases as CKD progresses and kidney function declines.
Market Snapshot

The launch of novel HIF inhibitor roxadustat will offset biosimilar erosion of Epogen to drive market growth.
Physicians expect to switch a significant portion of patients on stable erythropoiesis-stimulating agent (ESA) therapy to oral ESAs within three years of their launch.
By 2037, there will be an estimated 28% increase in total prevalent cases in the US, Japan, and five major EU markets.
Use of erythropoiesis-stimulating agents, the standard of care for anemia in CKD, may decline due to cost and safety concerns.
Pipeline therapies plan to capture market share by reducing costs and safety concerns associated with treatment.